Single tube Point-Of-Care multi-drug resistant tuberculosis test

单管床旁多重耐药结核病检测

• 批准号: 101552
• 金额: $ 167.03万
• 依托单位: ENIGMA DIAGNOSTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101552
• 关键词: Single; tube; Point; Care; multi

Enigma Diagnostics Ltd and its partners will develop a point of care test for multi-drug resistant tuberculosis (TB) that will run on the Enigma® Mini-Lab instrument and will be suitable for use outside traditional laboratories. For example, it could be used in clinics and surgeries, in both high and low per capita income countries. The test will use novel methods to process samples from patients with a newly invented system for detecting the bacteria that causes TB and detecting resistance to the drugs that are used to treat TB. It will be faster and more sensitive than tests used today and can distinguish the TB that affects people from those infecting other mammals (e.g. bovine TB). It will be safer than other methods as all the special chemistry takes place in a single closed tube.

Enigma Diagnostics Ltd及其合作伙伴将开发一种针对耐多药结核病（TB）的护理点测试，该测试将在Enigma® Mini-Lab仪器上运行，并适用于传统实验室之外。例如，它可以用于高人均收入和低人均收入国家的诊所和手术。该测试将使用新的方法来处理来自患者的样本，并使用新发明的系统来检测导致结核病的细菌和检测对用于治疗结核病的药物的耐药性。它将比今天使用的测试更快，更敏感，并且可以区分影响人类的结核病和感染其他哺乳动物的结核病（例如牛结核病）。它将比其他方法更安全，因为所有特殊的化学反应都发生在一个封闭的试管中。